6-K

                                    FORM 6-K

                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                            REPORT OF FOREIGN ISSUER
                      Pursuant to Rule 13a-16 or 15d-16 of
                       the Securities Exchange Act of 1934

                             Dated November 3, 1999

                    PHOENIX INTERNATIONAL LIFE SCIENCES INC.
                    ----------------------------------------

                 (TRANSLATION OF REGISTRANT'S NAME INTO ENGLISH)

                                2350 COHEN STREET
                                -----------------
                      SAINT LAURENT, QUEBEC CANADA H4R 2N6
                      ------------------------------------
                    (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)

         Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.

                  Form 20-F              Form 40-F    X   (commenced in calendar
                                                                  year 1998)

         Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the information to
the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.

                           Yes ____                  No   X

         If  "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b): ______________








                                   SIGNATURES


         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.


                                        PHOENIX INTERNATIONAL LIFE SCIENCES INC.
                                        ----------------------------------------
                                                   (Registrant)


Date:  November 3, 1999                      By: /s/ David Moszkowski
      -----------------                         -------------------------------
                                                       David Moszkowski
                                                       Senior Vice President and
                                                       Chief Financial Officer

EX-99.1

                                                                    EXHIBIT 99.1

Press Release - November 1, 1999
Phoenix International roles out production implementation of Oracle Clinical

The International Data Division of Phoenix International is pleased to announce
the global implementation of the clinical data management product, Oracle
Clinical v. 3.1.1 among its international Data Centres based in France, Spain,
UK and US.

This fully-validated application will form the framework for both regional and
global data management support for Phase II-IV clinical programs on behalf of
our pharmaceutical partners.

This implementation has driven common procedures and workflows and will
facilitate both local and distributed study management optimizing resources
within Phoenix International sites. Phoenix International and client standards
may be maintained and the product offers replication features to client Oracle
Clinical installations.

An international team was formed to champion this implementation and will
continue to manage additional key initiatives allied to our implementation of
Oracle Clinical including imaging and workflow solutions.

Phoenix International provides a wide spectrum of clinical, analytical,
preclinical, drug discovery support and ancillary services to the pharmaceutical
and biotechnology industries worldwide. Since beginning operations in 1989,
Phoenix International has grown to over 2,400 employees worldwide, of whom 215
have either medical degrees or PhDs and over 240 have masters degrees.

This release contains "forward-looking" statements regarding future results and
events, including statements regarding expected future revenues, earnings and
growth rates and goals and operating plans of management. Phoenix's actual
future results may differ significantly from the results discussed in the
forward-looking statements contained in this release. Factors that may cause
such a difference include, but are not limited to: the inability of Phoenix to
win new business at the levels required; the cancellation or delay of contracts;
risks associated with the management of growth and the ability to attract and
retain employees; risks of integrating newly acquired businesses; competition;
any claims for patent infringement; unanticipated costs in connection with Year
2000 conversion; the ability to obtain future financing; adverse regulatory
developments; foreign exchange rate fluctuations; and uncertainty surrounding
the Euro. "






For more information, contact:

JON WOOD
- --------
SENIOR DIRECTOR DATA DIVISION, EUROPE
- -------------------------------------
Tel:     +44 (0)1708 776022
Fax:     +44 (0)1708 725413
Email:   jwood@pils.com

Lilliam Kingsbury, Ph.D.
Senior Vice President, Data Division
Tel:     +1 215-540-8400
Fax:     +1 215-540-8433
Email: lilliam.kingsbury@pils-us.com